{"pmid":32470789,"title":"Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.","text":["Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.","recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs.","Med Hypotheses","Allahverdi Khani, M","SalehiRad, M","Darbeheshti, S","Motaghinejad, M","32470789"],"abstract":["recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs."],"journal":"Med Hypotheses","authors":["Allahverdi Khani, M","SalehiRad, M","Darbeheshti, S","Motaghinejad, M"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470789","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109871","keywords":["covid-19","immunotherapy","nicotinic agonist"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167110006669312,"score":9.490897,"similar":[{"pmid":32365556,"title":"Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease.","text":["Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease.","The cytokine storm is an abnormal production of inflammatory cytokines, due to the over-activation of the innate immune response. This mechanism has been recognized as a critical mediator of influenza-induced lung disease, and it could be pivotal for COVID-19 infections. Thus, an immunomodulatory approach targeting the over-production of cytokines could be proposed for viral aggressive pulmonary disease treatment. In this regard, the peroxisome proliferator-activated receptor (PPAR)-gamma, a member of the PPAR transcription factor family, could represent a potential target. Beside the well-known regulatory role on lipid and glucose metabolism, PPAR-gamma also represses the inflammatory process. Similarly, the PPAR-gamma agonist thiazolidinediones (TZDs), like pioglitazone, are anti-inflammatory drugs with ameliorating effects on severe viral pneumonia. In addition to the pharmacological agonists, also nutritional ligands of PPAR-gamma, like curcuma, lemongrass, and pomegranate, possess anti-inflammatory properties through PPAR-gamma activation. Here, we review the main synthetic and nutritional PPAR-gamma ligands, proposing a dual approach based on the strengthening of the immune system using pharmacological and dietary strategies as an attempt to prevent/treat cytokine storm in the case of coronavirus infection.","Molecules","Ciavarella, Carmen","Motta, Ilenia","Valente, Sabrina","Pasquinelli, Gianandrea","32365556"],"abstract":["The cytokine storm is an abnormal production of inflammatory cytokines, due to the over-activation of the innate immune response. This mechanism has been recognized as a critical mediator of influenza-induced lung disease, and it could be pivotal for COVID-19 infections. Thus, an immunomodulatory approach targeting the over-production of cytokines could be proposed for viral aggressive pulmonary disease treatment. In this regard, the peroxisome proliferator-activated receptor (PPAR)-gamma, a member of the PPAR transcription factor family, could represent a potential target. Beside the well-known regulatory role on lipid and glucose metabolism, PPAR-gamma also represses the inflammatory process. Similarly, the PPAR-gamma agonist thiazolidinediones (TZDs), like pioglitazone, are anti-inflammatory drugs with ameliorating effects on severe viral pneumonia. In addition to the pharmacological agonists, also nutritional ligands of PPAR-gamma, like curcuma, lemongrass, and pomegranate, possess anti-inflammatory properties through PPAR-gamma activation. Here, we review the main synthetic and nutritional PPAR-gamma ligands, proposing a dual approach based on the strengthening of the immune system using pharmacological and dietary strategies as an attempt to prevent/treat cytokine storm in the case of coronavirus infection."],"journal":"Molecules","authors":["Ciavarella, Carmen","Motta, Ilenia","Valente, Sabrina","Pasquinelli, Gianandrea"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32365556","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/molecules25092076","keywords":["ppar-gamma","ppar-gamma agonists","coronavirus infection","cytokine storm","inflammation","metabolism"],"locations":["PPAR","PPAR","PPAR","PPAR","Synthetic"],"e_drugs":["Pioglitazone","Thiazolidinediones","Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496289472512,"score":233.22157},{"pmid":32393438,"title":"Intelligent classification of platelet aggregates by agonist type.","text":["Intelligent classification of platelet aggregates by agonist type.","Platelets are anucleate cells in blood whose principal function is to stop bleeding by forming aggregates for hemostatic reactions. In addition to their participation in physiological hemostasis, platelet aggregates are also involved in pathological thrombosis and play an important role in inflammation, atherosclerosis, and cancer metastasis. The aggregation of platelets is elicited by various agonists, but these platelet aggregates have long been considered indistinguishable and impossible to classify. Here we present an intelligent method for classifying them by agonist type. It is based on a convolutional neural network trained by high-throughput imaging flow cytometry of blood cells to identify and differentiate subtle yet appreciable morphological features of platelet aggregates activated by different types of agonists. The method is a powerful tool for studying the underlying mechanism of platelet aggregation and is expected to open a window on an entirely new class of clinical diagnostics, pharmacometrics, and therapeutics.","Elife","Zhou, Yuqi","Yasumoto, Atsushi","Lei, Cheng","Huang, Chun-Jung","Kobayashi, Hirofumi","Wu, Yunzhao","Yan, Sheng","Sun, Chia-Wei","Yatomi, Yutaka","Goda, Keisuke","32393438"],"abstract":["Platelets are anucleate cells in blood whose principal function is to stop bleeding by forming aggregates for hemostatic reactions. In addition to their participation in physiological hemostasis, platelet aggregates are also involved in pathological thrombosis and play an important role in inflammation, atherosclerosis, and cancer metastasis. The aggregation of platelets is elicited by various agonists, but these platelet aggregates have long been considered indistinguishable and impossible to classify. Here we present an intelligent method for classifying them by agonist type. It is based on a convolutional neural network trained by high-throughput imaging flow cytometry of blood cells to identify and differentiate subtle yet appreciable morphological features of platelet aggregates activated by different types of agonists. The method is a powerful tool for studying the underlying mechanism of platelet aggregation and is expected to open a window on an entirely new class of clinical diagnostics, pharmacometrics, and therapeutics."],"journal":"Elife","authors":["Zhou, Yuqi","Yasumoto, Atsushi","Lei, Cheng","Huang, Chun-Jung","Kobayashi, Hirofumi","Wu, Yunzhao","Yan, Sheng","Sun, Chia-Wei","Yatomi, Yutaka","Goda, Keisuke"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393438","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7554/eLife.52938","keywords":["blood","cell biology","deep learning","human","human biology","imaging flow cytometry","medicine","microfluidics","platelet","thrombosis"],"topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1666627828084375552,"score":195.50343},{"pmid":32389847,"title":"Urgent need for evaluating agonists of Angiotensin-(1-7)/ Mas receptor axis for treatment of patients with COVID-19.","text":["Urgent need for evaluating agonists of Angiotensin-(1-7)/ Mas receptor axis for treatment of patients with COVID-19.","ACE2 being a receptor of entry of SARS-CoV-2 into the host cells, its upregulation has been implicated in increasing susceptibility of individuals to the infections. Clinical picture of COVID-19 suggests a role ACE2 blockade, rather than its overexpression, in causing the pathogenesis. ACE2 blockade results in increased Angiotensin II activity with simultaneous hampering of functions of Angiotensin-(1-7)/MasR axis. Acute respiratory distress due to interstitial pulmonary fibrosis, cardiomyopathy and shock reported in COVID-19 patients can be explained by imbalanced Angiotensin II and Angiotensin-(1-7) activities. Failure of Angiotensin II type 1 receptor blockers to control severity of SARS-CoV-2 infections indicates importance of simultaneous induction of Angiotensin-(1-7)/MasR axis for correcting pathological conditions in COVID-19 through its anti-fibrotic, anti-inflammatory, vasodilatory and cardioprotective roles. MasR agonists have also shown organ protective effects in a number of animal studies. Unfortunately, these agonists have not been tested in clinical studies. Their urgent evaluation in seriously ill COVID-19 patients is urgently warranted to reduce mortality due to the infections.","Int J Infect Dis","Shete, Ashwini","32389847"],"abstract":["ACE2 being a receptor of entry of SARS-CoV-2 into the host cells, its upregulation has been implicated in increasing susceptibility of individuals to the infections. Clinical picture of COVID-19 suggests a role ACE2 blockade, rather than its overexpression, in causing the pathogenesis. ACE2 blockade results in increased Angiotensin II activity with simultaneous hampering of functions of Angiotensin-(1-7)/MasR axis. Acute respiratory distress due to interstitial pulmonary fibrosis, cardiomyopathy and shock reported in COVID-19 patients can be explained by imbalanced Angiotensin II and Angiotensin-(1-7) activities. Failure of Angiotensin II type 1 receptor blockers to control severity of SARS-CoV-2 infections indicates importance of simultaneous induction of Angiotensin-(1-7)/MasR axis for correcting pathological conditions in COVID-19 through its anti-fibrotic, anti-inflammatory, vasodilatory and cardioprotective roles. MasR agonists have also shown organ protective effects in a number of animal studies. Unfortunately, these agonists have not been tested in clinical studies. Their urgent evaluation in seriously ill COVID-19 patients is urgently warranted to reduce mortality due to the infections."],"journal":"Int J Infect Dis","authors":["Shete, Ashwini"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389847","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ijid.2020.05.002","keywords":["ace2","angiotensin ii","angiotensin-(1-7)","covid-19","mas receptors"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528580050354176,"score":166.04886},{"pmid":32189428,"title":"Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","text":["Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells.","FEBS J","Olds, James L","Kabbani, Nadine","32189428"],"abstract":["The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells."],"journal":"FEBS J","authors":["Olds, James L","Kabbani, Nadine"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32189428","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1111/febs.15303","keywords":["addiction","infectious disease","pandemic","public health","tobacco"],"e_drugs":["Nicotine"],"topics":["Mechanism"],"weight":1,"_version_":1666138490570539009,"score":160.45778},{"pmid":32385628,"title":"Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?","text":["Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?","The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0-3.4%) to 12.6% (95% CI 10.6-14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9-8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7-8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19.","Intern Emerg Med","Farsalinos, Konstantinos","Barbouni, Anastasia","Niaura, Raymond","32385628"],"abstract":["The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0-3.4%) to 12.6% (95% CI 10.6-14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9-8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7-8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19."],"journal":"Intern Emerg Med","authors":["Farsalinos, Konstantinos","Barbouni, Anastasia","Niaura, Raymond"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385628","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11739-020-02355-7","keywords":["ace2","covid-19","hospitalization","inflammation","nicotine","sars-cov-2","smoking"],"locations":["China","China","China","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nicotine"],"topics":["Treatment"],"weight":1,"_version_":1666340102077415424,"score":153.3403}]}